The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 07, 2023
Filed:
Nov. 17, 2020
Applicant:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Inventors:
Assignee:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 38/17 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/7012 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01); A61K 38/16 (2006.01); A61K 47/10 (2017.01); C07K 14/71 (2006.01); C07K 16/22 (2006.01); A61K 47/12 (2006.01); A61K 9/19 (2006.01); A61K 31/4172 (2006.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39591 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 31/4172 (2013.01); A61K 31/7012 (2013.01); A61K 38/16 (2013.01); A61K 38/179 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); C07K 14/71 (2013.01); C07K 16/22 (2013.01); C07K 2318/20 (2013.01); C07K 2319/30 (2013.01);
Abstract
Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.